Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study
OBJECTIVES This genetics-based study aimed to evaluate the relationships of long-term lipid-lowering agents on lung-related diseases (LRD) outcomes. METHODS We extracted genetic variations of six drug target genes from a major genome-wide association study of low-density lipoprotein cholesterol (LDL...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | All Life |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/26895293.2024.2329440 |
| _version_ | 1797258319696494592 |
|---|---|
| author | Haifeng Yu Xiaofei Zhang Bian Wen Shuo Hu Bin Ni |
| author_facet | Haifeng Yu Xiaofei Zhang Bian Wen Shuo Hu Bin Ni |
| author_sort | Haifeng Yu |
| collection | DOAJ |
| description | OBJECTIVES This genetics-based study aimed to evaluate the relationships of long-term lipid-lowering agents on lung-related diseases (LRD) outcomes. METHODS We extracted genetic variations of six drug target genes from a major genome-wide association study of low-density lipoprotein cholesterol (LDL-C) in individuals predominantly of European ancestry to represent the effects of LDL-C-lowering treatment. We conducted drug-targeted Mendelian randomization and utilized a range of outcomes to capture evidence of adverse side effects related to the inhibition of the gene. RESULTS Our study did not find any significant association between genetically proxied APOB, CETP, HMGCR, NPCIL, PCSK9, and LDLR inhibition (equivalent to a one standard deviation reduction in LDL-C) with the risk of Small Cell Lung Cancer, Non-Small Cell Lung Cancer, idiopathic pulmonary fibrosis, and Pneumonia (P > 0.05). However, long-term inhibition of NPC1L that mimics the use of statin drugs may have contradictory effects on pulmonary edema (OR = 0.508, 95%CI = 0.328–0.786,P = 0.002) and chronic obstructive pulmonary disease (OR = 1.524, 95%CI = 1.099–2.115, P = 0.012). A series of sensitivity analyses and positive control analyses have been conducted to confirm the reliability of the results. CONCLUSIONS In conclusion, this study reveals inconsistent associations between genetic proxy inhibition of APOB, CETP, HMGCR, NPCIL, PCSK9 and LDLR with LRD in specific populations. |
| first_indexed | 2024-04-24T22:51:39Z |
| format | Article |
| id | doaj.art-b48cc6145f3b43e3b2f599d1b17a66c6 |
| institution | Directory Open Access Journal |
| issn | 2689-5307 |
| language | English |
| last_indexed | 2024-04-24T22:51:39Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | All Life |
| spelling | doaj.art-b48cc6145f3b43e3b2f599d1b17a66c62024-03-18T10:59:41ZengTaylor & Francis GroupAll Life2689-53072024-12-0117110.1080/26895293.2024.23294402329440Lipid-lowering drug targets and lung related diseases: a Mendelian randomization studyHaifeng Yu0Xiaofei Zhang1Bian Wen2Shuo Hu3Bin Ni4Department of Thoracic Surgery, The First Affiliated Hospital of Soochow UniversityDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow UniversityDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow UniversityDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow UniversityDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow UniversityOBJECTIVES This genetics-based study aimed to evaluate the relationships of long-term lipid-lowering agents on lung-related diseases (LRD) outcomes. METHODS We extracted genetic variations of six drug target genes from a major genome-wide association study of low-density lipoprotein cholesterol (LDL-C) in individuals predominantly of European ancestry to represent the effects of LDL-C-lowering treatment. We conducted drug-targeted Mendelian randomization and utilized a range of outcomes to capture evidence of adverse side effects related to the inhibition of the gene. RESULTS Our study did not find any significant association between genetically proxied APOB, CETP, HMGCR, NPCIL, PCSK9, and LDLR inhibition (equivalent to a one standard deviation reduction in LDL-C) with the risk of Small Cell Lung Cancer, Non-Small Cell Lung Cancer, idiopathic pulmonary fibrosis, and Pneumonia (P > 0.05). However, long-term inhibition of NPC1L that mimics the use of statin drugs may have contradictory effects on pulmonary edema (OR = 0.508, 95%CI = 0.328–0.786,P = 0.002) and chronic obstructive pulmonary disease (OR = 1.524, 95%CI = 1.099–2.115, P = 0.012). A series of sensitivity analyses and positive control analyses have been conducted to confirm the reliability of the results. CONCLUSIONS In conclusion, this study reveals inconsistent associations between genetic proxy inhibition of APOB, CETP, HMGCR, NPCIL, PCSK9 and LDLR with LRD in specific populations.http://dx.doi.org/10.1080/26895293.2024.2329440lipid-lowering drugstatinmendelian randomizationlung-related diseasesgene |
| spellingShingle | Haifeng Yu Xiaofei Zhang Bian Wen Shuo Hu Bin Ni Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study All Life lipid-lowering drug statin mendelian randomization lung-related diseases gene |
| title | Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study |
| title_full | Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study |
| title_fullStr | Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study |
| title_full_unstemmed | Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study |
| title_short | Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study |
| title_sort | lipid lowering drug targets and lung related diseases a mendelian randomization study |
| topic | lipid-lowering drug statin mendelian randomization lung-related diseases gene |
| url | http://dx.doi.org/10.1080/26895293.2024.2329440 |
| work_keys_str_mv | AT haifengyu lipidloweringdrugtargetsandlungrelateddiseasesamendelianrandomizationstudy AT xiaofeizhang lipidloweringdrugtargetsandlungrelateddiseasesamendelianrandomizationstudy AT bianwen lipidloweringdrugtargetsandlungrelateddiseasesamendelianrandomizationstudy AT shuohu lipidloweringdrugtargetsandlungrelateddiseasesamendelianrandomizationstudy AT binni lipidloweringdrugtargetsandlungrelateddiseasesamendelianrandomizationstudy |